Why is Bayer stock up today?

Bayer stock rose after the U.S. Solicitor General recommended a Supreme Court review related to Roundup. Investors read this as a step toward resolving a major uncertainty. The move came with higher volume, a fresh 52‑week high near €38, and hopes for lower litigation reserves if preemption is affirmed.

What is at stake in the glyphosate lawsuit?

About 65,000 Roundup cases remain. A Supreme Court review focusing on federal preemption could reduce many claims if federal labeling rules apply. That would likely lower legal costs and volatility. If review is denied, cases continue in state courts and uncertainty remains, which could pressure valuation.

What technical levels matter now for Bayer stock?

RSI is near 68 with a strong trend. Resistance sits around the Bollinger upper band near €38.6, while first support is near the middle band at €34.4. ATR is €0.96, implying roughly one‑euro daily ranges. A sustained close above €38.6 would reinforce bullish momentum.

When is Bayer’s next earnings report?

Bayer’s next scheduled earnings date is February 25, 2026. Investors should watch for updates on litigation reserves, cash conversion, and any changes to capital allocation. Guidance around the Pharmaceuticals pipeline will also be important for sentiment and for the sustainability of any re‑rating.

Global Market Insights

BAYN.DE Stock Today: January 2 — U.S. backs SCOTUS Roundup appeal

ByDanny Kontos January 3, 2026January 3, 2026

Bayer stock (BAYN.DE) rallied on January 2 after the U.S. Solicitor General recommended a Supreme Court review of Roundup cases. Investors see this as a path to resolve a major legal overhang. Shares traded around €38.00, up 4.35%, on heavier volume and a fresh 52‑week high. JPMorgan flagged potential reserve cuts of about €5 billion and up to 20% upside if preemption is affirmed. For German investors, the focus now is the certiorari decision expected in early January and what it could mean for cash, valuation, and momentum.